{"id":980834,"date":"2026-07-12T06:31:27","date_gmt":"2026-07-12T10:31:27","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/hemab-therapeutics-presents-new-clinical-data-from-hmb-002-in-von-willebrand-disease-and-introduces-hmb-003-for-heavy-menstrual-bleeding-at-the-isth-2026-congress\/"},"modified":"2026-07-12T06:31:27","modified_gmt":"2026-07-12T10:31:27","slug":"hemab-therapeutics-presents-new-clinical-data-from-hmb-002-in-von-willebrand-disease-and-introduces-hmb-003-for-heavy-menstrual-bleeding-at-the-isth-2026-congress","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/hemab-therapeutics-presents-new-clinical-data-from-hmb-002-in-von-willebrand-disease-and-introduces-hmb-003-for-heavy-menstrual-bleeding-at-the-isth-2026-congress\/","title":{"rendered":"Hemab Therapeutics Presents New Clinical Data from HMB-002 in Von Willebrand Disease and Introduces HMB-003 for Heavy Menstrual Bleeding at the ISTH 2026 Congress"},"content":{"rendered":"
\n

\n HMB-002 clinical data demonstrate proof of mechanism, with dose-dependent, greater than or equal to 2.4-fold peak increases in Von Willebrand Factor (VWF) and Factor VIII (FVIII), normalization of peak thrombin generation and activated partial thromboplastin time (APTT), and durability supporting potential monthly subcutaneous dosing<\/em>\n <\/p>\n

\n HMB-003 program announced as non-hormonal direct plasmin inhibitor with potent, selective and extended antifibrinolytic activity, designed to reduce bleeding across multiple settings beginning in heavy menstrual bleeding<\/em>\n <\/p>\n

CAMBRIDGE, Mass. and COPENHAGEN, Denmark, July 12, 2026 (GLOBE NEWSWIRE) — Hemab Therapeutics (Nasdaq:COAG), a clinical-stage biotechnology company developing therapies that reimagine the treatment of blood coagulation disorders to sustain life and human resilience, today presented new clinical data from HMB-002 in Von Willebrand disease (VWD) and announced the HMB-003 program at the International Society on Thrombosis and Haemostasis (ISTH) 2026 Congress in Paris, France.<\/p>\n

“Millions of people living with bleeding disorders including VWD and heavy menstrual bleeding have no reliable way to prevent excessive bleeds,” said Benny S\u00f8rensen, MD, PhD, CEO of Hemab. “Today, at ISTH 2026 we presented new HMB-002 data demonstrating proof of mechanism in VWD alongside preliminary clinical observations on treated bleeding events. We also unveiled HMB-003, a novel antifibrinolytic built on validated fatty-acid conjugated peptide technology, initially targeting heavy menstrual bleeding \u2013 an often-ignored vital sign. It affects one in three women, causing pain, iron-deficiency anemia, fatigue, stigma, and extensive lost days at school and work, with treatment options largely unchanged in decades. HMB-003 is non-hormonal, potent, and selective, engineered to cover the period, then wash out between cycles.”<\/p>\n

“The new HMB-002 data support a non-replacement approach in VWD: a single subcutaneous dose raising both VWF and FVIII more than 2-fold, with a favorable safety profile across every cohort,” said Priyanka Raheja, MD, Consultant Haematologist at Barts Health NHS Trust. “Building on 50 years of clinically validated treatment strategy, HMB-002 shows potential to change the VWD treatment paradigm by addressing the root cause of the disease; a durable increase, and for many patients potential normalization, of both VWF and FVIII.”<\/p>\n

\n
\n Program Presentations<\/u>
\n <\/strong>\n <\/p>\n

\n HMB-002<\/strong> is designed to address the underlying biological drivers of VWD through a non-replacement approach\u2014elevating the body’s endogenous levels of VWF and FVIII rather than infusing exogenous factor\u2014with early first-in-human data building a compelling case for this paradigm shift.<\/p>\n